Published in Cancer Weekly, April 10th, 2001
The median survival time of patients treated with a dose of 30 mL twice a day was 7.1 months, compared to 16.3 months for patients receiving a dose of 120 mL twice a day. A patient with metastatic renal cell carcinoma who does not respond to standard treatments is expected to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.